The ORR for TAS-102 and bevacizumab without leronl
Post# of 154722

As far as approval goes, God knows. Assuming that PD-L1 upregulation occurs and the addition of an ICI blows the doors off the study, and assuming the FDA has really changed its ways, an approval for third line at least as a no-brainer, IMO.

